| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,775 |
Appendix 3C
|
10 Jun 2025 8:38AM |
$49.300 |
$42.700 |
fallen by
13.39%
|
|
| Jameson Resources Limited (JAL) ORDINARY FULLY PAID |
Materials |
$39 |
Share Issue and Cleansing Notice
|
10 Jun 2025 8:38AM |
$0.040 |
$0.049 |
risen by
22.50%
|
|
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,775 |
Appendix 3C
|
10 Jun 2025 8:38AM |
$49.300 |
$42.700 |
fallen by
13.39%
|
|
| Waypoint REIT Limited (WPR) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,626 |
Update - Notification of buy-back - WPR
|
10 Jun 2025 8:38AM |
$2.630 |
$2.490 |
fallen by
5.32%
|
|
| Aura Energy Limited (AEE) ORDINARY FULLY PAID |
Energy |
$135 |
Aura strengthens executive team to drive Tiris development
|
10 Jun 2025 8:38AM |
$0.135 |
$0.135 |
fallen by
0%
|
|
| Ironbark Balanced Income Limited (IBC) ORDINARY FULLY PAID |
Financials |
$44 |
Update - Notification of buy-back - IBC
|
10 Jun 2025 8:38AM |
$0.440 |
$0.440 |
fallen by
0%
|
|
| Optiscan Imaging Limited (OIL) ORDINARY FULLY PAID |
Health Care |
$115 |
Optiscan Reveals InSpecta Device for Veterinary Medicine
|
10 Jun 2025 8:38AM |
$0.115 |
$0.110 |
fallen by
4.35%
|
|
OIL - Price-sensitive ASX Announcement
Full Release
Key Points
- Optiscan Imaging Limited has launched the InSpectra™ device for use in veterinary medicine.
- The device utilizes confocal endomicroscopy to enable real-time cellular imaging for veterinarians.
- It targets equine, companion animal, and exotic animal sectors, supporting diagnostics and research.
- The launch is part of a strategic initiative to leverage Optiscan's technology in new markets.
- There is a significant addressable global market in veterinary medicine for such imaging solutions.
- Initial commercialization efforts will focus on Australia with plans for global expansion.
- The move aligns with Optiscan's broader goal to diversify its technology applications and revenue streams.
- InSpectra™ is positioned as a minimally invasive, advanced diagnostic tool to improve veterinary patient outcomes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| TrivarX Ltd (TRI) ORDINARY FULLY PAID |
Health Care |
$24 |
Proposed issue of securities - TRI
|
10 Jun 2025 8:38AM |
$0.010 |
$0.021 |
risen by
110%
|
|
| Titan Minerals Limited (TTM) ORDINARY FULLY PAID |
Materials |
$239 |
Dynasty Drilling Continues to Deliver Results
|
10 Jun 2025 8:38AM |
$0.395 |
$0.830 |
risen by
110.13%
|
|
TTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Titan Minerals Limited released new high-grade gold and silver assay results from the Dynasty Gold Project.
- Drilling has expanded the known mineralized footprint and confirmed mineralization continuity at depth and along strike.
- Multiple mineralized structures have been identified, supporting the geological model.
- Recent results will assist in resource estimation and drive future exploration activities.
- Operational updates include environmental and community engagement progress.
- The company is focused on advancing Dynasty toward development through systematic drilling and resource growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Native Mineral Resources Holdings Limited (NMR) ORDINARY FULLY PAID |
Materials |
$53 |
NMR targets Blackjack first gold pour in July 2025
|
10 Jun 2025 8:38AM |
$0.195 |
$0.048 |
fallen by
75.38%
|
|
| Dyno Nobel Limited (DNL) ORDINARY FULLY PAID |
Materials |
$5,864 |
Update - Notification of buy-back - DNL
|
10 Jun 2025 8:38AM |
$2.630 |
$3.340 |
risen by
27%
|
|
| Firebrick Pharma Limited (FRE) ORDINARY FULLY PAID |
Health Care |
$15 |
Nasodine Phase 3 Common Cold Trial Published
|
10 Jun 2025 8:38AM |
$0.067 |
$0.053 |
fallen by
20.90%
|
|
| RocketDNA Ltd (RKT) ORDINARY FULLY PAID |
Information Technology |
$29 |
Release of Securities from Voluntary Escrow
|
10 Jun 2025 8:37AM |
$0.011 |
$0.024 |
risen by
118.18%
|
|
| Prodigy Gold NL (PRX) ORDINARY FULLY PAID |
Materials |
$27 |
Entitlement Offer Booklet
|
10 Jun 2025 8:37AM |
$0.003 |
$0.079 |
risen by
3,060%
|
|
PRX - Price-sensitive ASX Announcement
Full Release
Key Points
- Prodigy Gold NL (PRX) is undertaking a fully underwritten 1 for 3.7 pro-rata non-renounceable entitlement offer to raise approximately $2.4 million.
- The offer price is $0.036 per new share, representing a discount to the last closing price and the 5-day volume weighted average price prior to the announcement.
- The entitlement offer is underwritten by Canaccord Genuity (Australia) Limited.
- Funds raised will be used primarily for exploration activities at the Lake Mackay Project, as well as working capital and costs of the offer.
- Eligible shareholders are those on the record date with registered addresses in Australia or New Zealand.
- The offer is non-renounceable, meaning entitlements cannot be traded or sold on the ASX.
- Directors and related parties may participate up to their entitlement, subject to shareholder approval if required.
- New shares issued under the offer will rank equally with existing shares from their date of issue.
- The document outlines key risks associated with the offer, including exploration risks, funding risks, and market risks.
- Tax implications of participating in the offer are discussed and shareholders are advised to consult tax advisors.
- A detailed timetable for the offer process, including key dates for opening, closing, and allotment of shares, is provided.
- The booklet provides instructions to shareholders on how to accept their entitlement and submit applications.
- Contact details for the share registry and company are included for shareholder enquiries.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$634 |
Imricor Receives CE Mark Approval for NorthStar
|
10 Jun 2025 8:37AM |
$1.660 |
$1.975 |
risen by
18.98%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Imricor received CE Mark approval for NorthStar™ 3D Mapping System.
- Approval allows commercial sale in the European Union and CE Mark-accepting markets.
- NorthStar is used for real-time 3D mapping during cardiac ablation in MRI environments.
- Aims to advance MRI-guided electrophysiology with improved safety and workflow.
- System integrates with Imricor's Advantage-MR™ EP Recorder/Stimulator and Vision-MR™ Ablation Catheter.
- Compatible with Siemens Healthineers' MRI platform.
- CE Mark approval follows successful clinical evaluations.
- Represents a major milestone for Imricor's European expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Computershare Limited (CPU) ORDINARY FULLY PAID |
Industrials |
$17,774 |
Update - Notification of buy-back - CPU
|
10 Jun 2025 8:37AM |
$41.080 |
$30.730 |
fallen by
25.19%
|
|
| Solvar Limited (SVR) ORDINARY FULLY PAID |
Financials |
$297 |
Update - Notification of buy-back - SVR
|
10 Jun 2025 8:37AM |
$1.605 |
$1.570 |
fallen by
2.18%
|
|
| EZZ Life Science Holdings Limited (EZZ) ORDINARY FULLY PAID |
Health Care |
$30 |
EZZ Enters SE Asia with Multi Year Distribution Agreement
|
10 Jun 2025 8:37AM |
$1.500 |
$0.640 |
fallen by
57.33%
|
|
EZZ - Price-sensitive ASX Announcement
Full Release
Key Points
- EZZ Life Science Holdings Limited signed a multi-year distribution agreement with Austech Global (Asia) Company Limited.
- Austech gains exclusive distribution rights for EZZ products in Southeast Asia.
- Target markets include Malaysia, Singapore, Thailand, and Vietnam.
- The agreement supports EZZ’s international growth and expansion strategy.
- There is a minimum order commitment from Austech, providing revenue certainty.
- Demand for health and wellness products is rising in Southeast Asia.
- The partnership is expected to enhance EZZ’s market presence and brand visibility.
- EZZ continues its commitment to innovative health solutions.
- The agreement aims to generate long-term value for EZZ shareholders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Shine Justice Ltd (SHJ) ORDINARY FULLY PAID |
Consumer Discretionary |
$127 |
Update - Notification of buy-back - SHJ
|
10 Jun 2025 8:37AM |
$0.710 |
$0.750 |
risen by
5.63%
|
|
| ResMed Inc. (RMD) CDI 10:1 FOREIGN EXEMPT NYSE |
Health Care |
$16,222 |
Notice of Proposed Sale of Securities
|
10 Jun 2025 8:37AM |
$38.230 |
$28.730 |
fallen by
24.85%
|
|
| Middle Island Resources Limited (MDI) ORDINARY FULLY PAID |
Materials |
$24 |
Change in substantial holding
|
10 Jun 2025 8:37AM |
$0.025 |
$0.024 |
fallen by
4%
|
|
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$581 |
Weekly NTA 06.06.2025
|
10 Jun 2025 8:37AM |
$3.230 |
$2.610 |
fallen by
19.20%
|
|
| Platinum Capital Limited (PMC) ORDINARY FULLY PAID |
Financials |
- |
Ceasing to be a substantial holder
|
10 Jun 2025 8:37AM |
$1.340 |
$1.765 |
risen by
31.72%
|
|
| Solis Minerals Ltd (SLM) ORDINARY FULLY PAID |
Materials |
$21 |
Solis Minerals seeks delisting from TSXV
|
10 Jun 2025 8:37AM |
$0.100 |
$0.080 |
fallen by
20%
|
|
SLM - Price-sensitive ASX Announcement
Full Release
Key Points
- Solis Minerals Ltd is seeking voluntary delisting from the TSX Venture Exchange (TSXV).
- The delisting decision is aimed at streamlining the company's capital markets presence and reducing compliance costs.
- Solis Minerals will retain its listings on the Australian Securities Exchange (ASX) and the OTCQB Market in the US.
- The company believes these alternative listings provide greater value and alignment with its shareholder demographics.
- Ongoing business operations and exploration activities are not expected to be impacted by the TSXV delisting.
- Shareholders are advised that the delisting does not affect the validity or tradability of their shares on other exchanges.
- The formal delisting process requires regulatory approval and notification to shareholders.
- The announcement was made on June 20, 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vection Technologies Ltd (VR1) ORDINARY FULLY PAID |
Information Technology |
$70 |
Vection launches Algho AI Sign Language on AWS Marketplace
|
10 Jun 2025 8:37AM |
$0.021 |
$0.030 |
risen by
42.86%
|
|
VR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Vection Technologies Ltd launched Algho AI Sign Language on AWS Marketplace.
- Algho AI Sign Language provides real-time AI-driven sign language interpretation.
- The solution aims to enhance digital accessibility for Deaf and hard-of-hearing users.
- It can be integrated across web, mobile, and digital kiosks.
- Designed to help organizations and businesses meet accessibility requirements.
- Available globally through AWS Marketplace for easier deployment.
- The launch supports Vection Technologies’ strategy of innovation and expansion.
- Demonstrates the company’s focus on leveraging AI for inclusivity and accessibility.
- The solution is expected to accelerate adoption among enterprise and public sector clients.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
